Monoclonal antibodies inhibiting MMP-9 activity alleviate peripheral neuropathy in diabetic mice.

Monoclonal antibodies targeting MMP-9 reduce neuropathic pain and improve nerve healing in diabetic mice, showing promise for treating diabetic peripheral neuropathy.

• Why it matters: Diabetic peripheral neuropathy causes significant pain and tissue damage, yet no effective treatments exist to halt or reverse nerve degeneration, highlighting a critical unmet need.
• What they did: Researchers developed selective monoclonal antibodies that inhibit MMP-9 activity and administered them systemically to diabetic mouse models, assessing pain, nerve health, and wound healing.
• The result: Treatment alleviated pain, enhanced nerve regeneration, and improved wound healing, suggesting MMP-9 mAbs could serve as disease-modifying therapies for diabetic neuropathy in humans.